Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment

P L A Fraaij; G Verweel; A M C van Rossum; N G Hartwig; D M Burger; R de Groot

doi:10.1007/s15010-007-6068-1

Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment

Infection. 2007 Jun;35(3):186-9. doi: 10.1007/s15010-007-6068-1.

Authors

P L A Fraaij¹, G Verweel, A M C van Rossum, N G Hartwig, D M Burger, R de Groot

Affiliation

¹ Dept. of Pediatrics, Erasmus MC-Sophia Children's Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands. p.fraaij@erasmusmc.nl

Abstract

We here present the study results of 21 HIV-1 infected children who were treated with indinavir plus low-dose ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. Although this q12h HAART regimen had potent antiretroviral activity, it was frequently associated with side effects and discontinuation of therapy.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antiretroviral Therapy, Highly Active / adverse effects
Antiretroviral Therapy, Highly Active / methods
Child
Child, Preschool
Female
HIV Infections / drug therapy*
HIV Protease Inhibitors / adverse effects*
HIV-1 / drug effects*
Humans
Indinavir / adverse effects
Infant
Male
Ritonavir / adverse effects

Substances

HIV Protease Inhibitors
Indinavir
Ritonavir